Descovy demonstrated continued noninferiority to Truvada for HIV pre-exposure prophylaxis and statistically significant differences over Truvada for pre-specified secondary end points.
The FDA as approved updated labeling for all efavirenz-containing products with additions to the Warnings and Precautions and Adverse Reactions: Postmarketing Experience sections.
Researchers examined the prevalence of HIV drug resistance patterns among HIV-infected infants using 3 nationally representative surveys in South Africa that evaluated the effectiveness of national programs to prevent mother-to-child transmission of HIV.
California is the first state to allow pharmacists to dispense HIV prevention pills to patients without a doctor’s prescription.
Investigators compared a dolutegravir-based regimen with an EFV400-based reference regimen in adults in Cameroon infected with HIV-1, considering viral suppression at week 48, in particular.
The FDA has approved Descovy for HIV-1 PrEP in at-risk adults and adolescents (≥35kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at-risk from receptive vaginal sex.
HIV treatment and virologic failure, and sustained viral response at week 12 or 24 were not different among patients who did or did not undergo a switch in their antiretroviral therapy regimen prior to DAA treatment.
Approximately 1 in 5 people with HIV also has prevalent DM, and control of hemoglobin A1c levels in these patients may have a beneficial effect on CD4 counts.
Direct-acting antiviral agents for treatment of hepatitis C virus may have higher sustained virologic responses in people coinfected with hepatitis B and hepatitis C viruses.
Switching antiretroviral therapy in virologically suppressed patients provides a robust option for preserving bone health while continuing suppressive HIV treatment.
